Discussion on antiplatelet aggregation treatment options in high sensitive C-reactive protein less than 2 mg/L in patients with angina pectoris / 天津医药
Tianjin Medical Journal
; (12): 967-969, 2016.
Article
em Zh
| WPRIM
| ID: wpr-496375
Biblioteca responsável:
WPRO
ABSTRACT
Objective To evaluate the feasibility of application of single and dual antiplatelet aggregation therapy in high sensitive C-reactive protein (hs-CRP) level in patients with angina pectoris. Methods Ninety-six hospitalized patients with angina 6~48 h (hs-CRP0.05). There were no significant differences in events of composite end points in patients after treatment between two groups (P > 0.05). Conclusion For angina pectoris patients with hs-CRP<2 mg/L, the risk of cardiovascular events is relatively little. There is no obvious difference in curative effect between single and dual antiplatelet aggreration therapies.
Texto completo:
1
Base de dados:
WPRIM
Tipo de estudo:
Diagnostic_studies
Idioma:
Zh
Revista:
Tianjin Medical Journal
Ano de publicação:
2016
Tipo de documento:
Article